CD8A and neoplasm: An in vivo CRISPR–Cas9 mutagenesis screen found that targeting the ribonuclease REGNASE-1 reprogrammed CD8+ T cells into long-lived effector cells with improved mitochondrial fitness and anti-tumor responses.